Matinas Biopharma (MTNB) Competitors $1.03 0.00 (0.00%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.01 -0.02 (-1.46%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MTNB vs. CING, MRKR, BIVI, QTTB, MTEX, PRPH, RVPH, CARM, LPCN, and GELSShould you be buying Matinas Biopharma stock or one of its competitors? The main competitors of Matinas Biopharma include Cingulate (CING), Marker Therapeutics (MRKR), BioVie (BIVI), Q32 Bio (QTTB), Mannatech (MTEX), ProPhase Labs (PRPH), Reviva Pharmaceuticals (RVPH), Carisma Therapeutics (CARM), Lipocine (LPCN), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry. Matinas Biopharma vs. Its Competitors Cingulate Marker Therapeutics BioVie Q32 Bio Mannatech ProPhase Labs Reviva Pharmaceuticals Carisma Therapeutics Lipocine Gelteq Matinas Biopharma (NYSE:MTNB) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do analysts prefer MTNB or CING? Cingulate has a consensus price target of $26.00, suggesting a potential upside of 497.70%. Given Cingulate's stronger consensus rating and higher probable upside, analysts plainly believe Cingulate is more favorable than Matinas Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, MTNB or CING? Cingulate is trading at a lower price-to-earnings ratio than Matinas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas BiopharmaN/AN/A-$22.94M-$3.86-0.27CingulateN/AN/A-$15.55M-$8.48-0.51 Does the media prefer MTNB or CING? In the previous week, Cingulate had 5 more articles in the media than Matinas Biopharma. MarketBeat recorded 5 mentions for Cingulate and 0 mentions for Matinas Biopharma. Cingulate's average media sentiment score of 0.63 beat Matinas Biopharma's score of 0.00 indicating that Cingulate is being referred to more favorably in the news media. Company Overall Sentiment Matinas Biopharma Neutral Cingulate Positive Which has more risk and volatility, MTNB or CING? Matinas Biopharma has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.79, meaning that its share price is 179% less volatile than the S&P 500. Do institutionals and insiders hold more shares of MTNB or CING? 11.8% of Matinas Biopharma shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 4.6% of Matinas Biopharma shares are held by insiders. Comparatively, 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is MTNB or CING more profitable? Matinas Biopharma's return on equity of -123.06% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -123.06% -94.28% Cingulate N/A -229.78%-142.28% SummaryCingulate beats Matinas Biopharma on 8 of the 13 factors compared between the two stocks. Get Matinas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTNB vs. The Competition Export to ExcelMetricMatinas BiopharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$5.24M$839.03M$5.60B$20.79BDividend YieldN/A4.84%5.24%3.71%P/E Ratio-0.211.1727.9627.89Price / SalesN/A241.37430.5742.50Price / CashN/A17.6937.4622.63Price / Book0.236.528.044.57Net Income-$22.94M-$23.68M$3.18B$988.81M7 Day Performance12.81%1.60%3.63%0.20%1 Month Performance17.05%12.39%4.04%3.93%1 Year PerformanceN/A5.76%29.56%10.27% Matinas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTNBMatinas BiopharmaN/A$1.03flatN/AN/A$5.24MN/A-0.2130CINGCingulate3.1041 of 5 stars$4.42+3.3%$26.00+488.2%+805.5%$18.17MN/A-0.5220News CoverageMRKRMarker Therapeutics4.6571 of 5 stars$1.57-1.9%$13.17+738.6%-64.8%$18.10M$6.59M-1.1860News CoveragePositive NewsGap UpBIVIBioVie1.1359 of 5 stars$8.10-15.6%N/A+63.7%$17.83MN/A-1.0210News CoveragePositive NewsQTTBQ32 Bio2.7015 of 5 stars$1.36-5.6%$12.17+794.6%-88.1%$17.57M$1.16M-0.2839Gap DownMTEXMannatech1.398 of 5 stars$8.90-3.8%N/A+20.4%$17.49M$117.87M-89.00250High Trading VolumePRPHProPhase Labs0.6749 of 5 stars$0.44+5.6%N/A-87.8%$17.39M$5.85M-0.35130Positive NewsRVPHReviva Pharmaceuticals3.2247 of 5 stars$0.37+1.9%$9.00+2,353.0%-69.2%$17.28MN/A-0.465Gap UpCARMCarisma Therapeutics3.2732 of 5 stars$0.40-2.0%$1.93+387.3%-66.7%$16.84M$19.63M-0.2520LPCNLipocine2.5558 of 5 stars$3.11+0.3%$9.00+189.4%-57.4%$16.59M$11.20M-3.0510GELSGelteqN/A$1.67-2.9%N/AN/A$16.23M$100K0.00N/AGap Down Related Companies and Tools Related Companies CING Alternatives MRKR Alternatives BIVI Alternatives QTTB Alternatives MTEX Alternatives PRPH Alternatives RVPH Alternatives CARM Alternatives LPCN Alternatives GELS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MTNB) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Matinas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
